title: The diverse distribution of risk factors between breast cancer subtypes of ER, PR and HER2: a 10-year retrospective multi-center study in China.
abstract: BACKGROUND
  Hormone receptors, human epidermal growth factor receptor 2 and some risk factors determine therapies and prognosis of breast cancer. The risk factors distributed differently between patients with receptors. This study aimed to investigate the distribution of risk factors between subtypes of breast cancer by the 3 receptors in Chinese native women with a large sample size.
  
  
  METHODS
  The multi-center study analyzed 4211 patient medical records from 1999 to 2008 in 7 regions of China. Data on patients' demographic information, risk factors (menopausal status, parity, body mass index) and receptor statuses were extracted. Breast cancer subtypes included ER (+/-), PR (+/-), HER2 (+/-), 4 ER/PR and 4 molecular subtypes. Wilcoxon and Chi-square tests were used to estimate the difference. The unconditional logistic regression model was used for analysis, and presented p-value after Bonferroni correction in the results.
  
  
  RESULTS
  Compared to patients with negative progesterone receptor, the positive patients were younger at diagnosis, and reported less likely in postmenopausal status and lower parity (p<0.05). Comparing with the subtype of ER+/PR+, ER+/PR- subtype were 4-year older at diagnosis (OR = 1.02), more likely to be postmenopausal (OR = 1.91) and more likely to have >1 parity (OR = 1.36) (p<0.05); ER-/PR- subtype were more likely to be postmenopausal (OR = 1.33) and have >1 parity (OR = 1.19) (p<0.05). In contrast to the luminal A subtype, triple negative subtype had a lower BMI (OR = 0.96) and ORs of overweight and obesity reduced by >20% (p<0.05).
  
  
  CONCLUSIONS
  In this study, it was found that Chinese female patients did have statistically significant differences of age, menopausal status, parity and body mass index between breast cancer subtypes. Studies are warranted to further investigate the risk factors between subtypes, which was meaningful for prevention and treatment among Chinese females.
authors: Departments of Epidemiology, Pathology, Cancer Institute & Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
authors: Qingkun
authors: Q
authors: Song
authors: Rong
authors: R
authors: Huang
authors: Jing
authors: J
authors: Li
authors: Jinhu
authors: J
authors: Fan
authors: Shan
authors: S
authors: Zheng
authors: Bin
authors: B
authors: Zhang
authors: Hongjian
authors: H
authors: Yang
authors: Zhonghua
authors: Z
authors: Tang
authors: Jianjun
authors: J
authors: He
authors: Xiaoming
authors: X
authors: Xie
authors: Hui
authors: H
authors: Li
authors: Jiayuan
authors: J
authors: Li
authors: Youlin
authors: Y
authors: Qiao
mesh_terms: D000328:Adult; D015992:Body Mass Index; D001943:Breast Neoplasms / Q000175:diagnosis* / Q000235:genetics* / Q000473:pathology; D002681:China; D005260:Female; D015870:Gene Expression; D006801:Humans; D016015:Logistic Models; D008875:Middle Aged; D010298:Parity; D017698:Postmenopause; D011247:Pregnancy; D017697:Premenopause; D011379:Prognosis; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000235:genetics*; D011960:Receptors, Estrogen / Q000235:genetics*; D011980:Receptors, Progesterone / Q000235:genetics*; D012189:Retrospective Studies; D012307:Risk Factors
chemical_list: D018719:Erb-b2 Receptor Tyrosine Kinases; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; C508053:ERBB2 protein, human
references: Arch Pathol Lab Med. 2003 May;127(5):549-53
references: 12708896
references: Int J Cancer. 2012 Dec 15;131(12):2869-77
references: 22407763
references: Am J Epidemiol. 2011 Sep 15;174(6):661-71
references: 21768404
references: Am J Epidemiol. 2009 May 15;169(10):1251-9
references: 19318616
references: Breast Cancer Res Treat. 1982;2(1):5-73
references: 6216933
references: Breast Cancer Res. 2006;8(4):R43
references: 16859501
references: Int J Cancer Suppl. 1990;5:5-21
references: 2258266
references: Tumori. 2010 Jan-Feb;96(1):103-10
references: 20437866
references: Int J Cancer. 2006 Oct 1;119(7):1683-9
references: 16646051
references: CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108
references: 15761078
references: Cancer. 1993 May 15;71(10):3185-8
references: 8490850
references: J Natl Cancer Inst. 2011 Feb 2;103(3):250-63
references: 21191117
references: JAMA. 2006 Jun 7;295(21):2492-502
references: 16757721
references: J Clin Oncol. 2000 May;18(10):2059-69
references: 10811671
references: Int J Cancer. 2012 Dec 1;131(11):2622-31
references: 22377956
references: Cancer Causes Control. 2012 Jan 28;:
references: 22286371
references: Cancer Epidemiol Biomarkers Prev. 2004 Oct;13(10):1558-68
references: 15466970
references: BMC Cancer. 2011 Aug 22;11:364
references: 21859480
references: Int J Cancer. 2007 Sep 1;121(5):1079-85
references: 17487843
references: Ann Epidemiol. 2007 Apr;17(4):304-12
references: 17174568
references: Breast Cancer Res. 2010;12(1):R10
references: 20146796
references: J Natl Cancer Inst. 2012 Jul 18;104(14):1094-101
references: 22773826
references: Pathol Oncol Res. 2011 Sep;17(3):753-8
references: 21479875
references: Obesity (Silver Spring). 2009 May;17(5):1070-6
references: 19180069
references: Clin Med Res. 2009 Jun;7(1-2):4-13
references: 19574486
references: Breast Cancer Res. 2007;9(1):R6
references: 17239243